SETD2 and nonpapillary renal cell carcinoma: NOD scid gamma mice were injected subcutaneously with SETD2 mutant ccRCC-derived A498 cells and approximately a month later, mice bearing tumors measuring ≥150 mm3 were randomized to treatment with vehicle (control) or AZD8186.